source
- GSK terminates $700 million Alector partnership after recent trial setbacksGSK has decided to end its collaboration with Alector, a biotech focused on neurodegenerative diseases. The agreement originally included a $700 million upfront payment. The move follows two high-…
- Mid-year roundup highlights top health-tech trends in 2026The editorial team notes that the first half of 2026 has been unusually active for health technology. Five major developments have been identified as the most significant so far. One clear theme i…